Latest news with #precisionmedicine
Associated Press
11 hours ago
- Business
- Associated Press
TEM Investors with Large Losses Should Contact Robbins LLP for Information About Leading the Securities Fraud Class Action Against TEM
SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025. Tempus purports to be provide Artificial Intelligence ('AI') enabled precision medicine solutions. For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that Tempus AI, Inc. (TEM) Misled Investors Regarding its Business Prospects According to the complaint, defendants failed to disclose: (1) Tempus inflated the value of contract agreements, many of which were with related parties, included non-binding opt-ins and/or were self-funded; (2) the credibility and substance of the joint venture with SoftBank was at risk because it gave the appearance of 'round-tripping' capital to create revenue for Tempus; (3) Tempus-acquired Ambry had a business model based on aggressive and potentially unethical billing practices that risked scrutiny and unsustainability; (4) AstraZeneca had reduced its financial commitments to Tempus through a questionable 'pass-through payment' via a joint agreement between it, the Company and Pathos AI; and (5) the foregoing issues revealed weakness in core operations and revenue prospects. The complaint alleges that on May 28, 2025, Spruce Point Capital Management, LLC issued a report on Tempus that raised numerous red flags over Tempus' management, operations and financial reporting. The Spruce Point Report scrutinized Tempus on an array of issues, including: (1) defendant Eric Lefkofsky and his associates have a history cashing out of companies before public shareholders incur losses or lackluster returns; (2) Tempus' actual AI capabilities are overstated; (3) board members and other executives have been associated with troubled companies that restated financial results; (4) signs of aggressive accounting and financial reporting; (4) issues with the AstraZeneca and Pathos AI deal that merit scrutiny; and (5) the Company's recent financial guidance reveals weakness in core operations. On this news, the price of Tempus common stock fell $12.67 per share, or 19.23%, from a closing price of $65.87 per share on May 27, 2025, to a closing price of $53.20 per share on May 28, 2025. What Now: You may be eligible to participate in the class action against Tempus AI, Inc. Shareholders who want to serve as lead plaintiff for the class should contact the firm. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here . All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Tempus AI, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today. Attorney Advertising. Past results do not guarantee a similar outcome.
Yahoo
17 hours ago
- Health
- Yahoo
Zollinger Ellison Syndrome Market Analysis Report 2025: Novartis, GSK, Bayer, Pfizer, and Bristol Myers Squibb Dominate
Enhanced treatment options, precision medicine, and advanced diagnostics are fueling growth across major markets Zollinger Ellison Syndrome Market Dublin, June 27, 2025 (GLOBE NEWSWIRE) -- The "Zollinger Ellison Syndrome Market Report and Forecast 2025-2034" report has been added to Zollinger Ellison Syndrome market was valued at USD 1.34 billion in 2024 driven by innovations in treatment options across the 8 major markets. It is expected to grow at a CAGR of 4.40% during the forecast period of 2025-2034 and attain a market value of USD 2.07 billion by 2034. Market growth is driven by the rising awareness of rare disorders, advanced technologies, and improvements in the availability of medicines and surgical treatments. Emphasis on precision medicine and treatment for rare diseases is further fueling the expansion of the in incidence of rare disorders to Drive Market ExpansionThe increasing incidence of rare diseases like Zollinger-Ellison Syndrome is driving market growth. According to the United States Food and Drug Administration's 2024 report, over 7,000 rare diseases affect more than 30 million people in the United States alone. As healthcare accessibility improves and awareness among professionals and patients rises, earlier diagnosis and better management will likely drive demand for specialized treatments, creating significant market opportunities. Based on the treatment, the market is divided into medications, surgery, and cancer therapies. Medications are expected to hold a significant share of the market as they have shown the positive results in controlling the overproduction of acid and symptomatic relief. Proton pump inhibitors and H2 receptor antagonists are the most frequently used drugs, but novel targeted cancer therapies are becoming more popular and are also reshaping the treatment of severe and advanced cases. Based on region, the market is divided into the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. The United States holds a substantial share of the market, as it has advanced healthcare infrastructure, high disease awareness, and considerable investments in rare disease research. Access to innovative diagnostic tools and therapies, coupled with a robust pharmaceutical industry, makes it a leader in the advancement of diagnosis and treatment of Zollinger Ellison syndrome. The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:Increased Emphasis on Precision Medicine: The market is witnessing increased adoption of precision medicine approaches, using genetic profiling to identify disease-specific treatments. Personalized medicine strategies are driving better therapeutic outcomes and improved patient satisfaction, fueling innovation, and expanding treatment options tailored to individual Advancements in Diagnostic Technologies to Boost Zollinger Ellison Syndrome Market Value: Emerging diagnostic tools, such as high-resolution imaging and molecular testing, are improving early detection rates for Zollinger Ellison syndrome. These advances improve the accuracy of diagnosis, allowing for timely treatment initiation and contributing to the growth of the market by enabling better patient of Long-Acting Drugs to Enhance Zollinger Ellison Syndrome Market Growth: The introduction of long-acting formulations is another prominent market trend. These drugs guarantee extended symptom control, and enhanced compliance among patients, promoting growth in the pharmacological treatment segment of the of Telemedicine Services to Fuel Zollinger Ellison Syndrome Market Demand: Telemedicine is increasingly being used in the management of Zollinger Ellison syndrome. Patients can reach out for proper specialized care, helping in the improvement of patient engagement, ensuring timely follow-ups, and supporting better disease monitoring, especially in remote or underserved Players in the Zollinger Ellison Syndrome MarketThe key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:Novartis AGNovartis, headquartered in Basel, Switzerland, was established in 1996. Its prominent product, Sandostatin, is widely used in the treatment of Zollinger-Ellison syndrome, among other conditions. This injectable medication, containing octreotide acetate, helps control symptoms and reduce growth hormone levels, often in combination with proton pump inhibitors or H2-antagonist Inc., headquartered in New York City and established in 1849, is a leading pharmaceutical company known for innovative healthcare solutions. Its product, Protonix, which includes Protonix Delayed-Release Pantoprazole Sodium Tablets and Protonix Delayed-Release Pantoprazole Sodium Granules, is used to treat conditions such as Zollinger-Ellison Syndrome. Protonix, a proton pump inhibitor (PPI), is prescribed for pathological hypersecretory conditions, providing critical relief in reducing excessive stomach acid N.V., established in 1961 and headquartered in Hertfordshire, England, is a global pharmaceutical company. It offers a wide range of products, including Lansoprazole delayed-release orally disintegrating tablets (ODT), which are used to treat conditions such as Zollinger-Ellison syndrome. It focuses on providing high-quality medicines International International Inc., established in 1931 and headquartered in Deerfield, Illinois, is a global leader in pharmaceuticals, specializing in injectable products. In December 2024, the company launched Pantoprazole Sodium in 0.9% Sodium Chloride Injection, aimed at treating Zollinger-Ellison Syndrome (ZE). This addition supports their commitment to advancing critical care Questions Answered in the Zollinger Ellison Syndrome Market Report What was the Zollinger Ellison syndrome market value in 2024? What is the Zollinger Ellison syndrome market forecast outlook for 2025-2034? What are the regional markets covered in the report? What is the market segmentation based on treatment? What is the market breakup based on end users? What is the market breakup based on the distribution channels? What major factors aid the Zollinger Ellison syndrome market demand? How has the market performed so far and how is it anticipated to perform in the coming years? What are the major drivers, opportunities, and restraints in the market? What are the major trends influencing the market? Which regional market is expected to dominate the market share in the forecast period? Which country is likely to experience elevated growth during the forecast period? Who are the key players involved in the Zollinger Ellison syndrome market? What are the current unmet needs and challenges in the market? How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics? Key Attributes Report Attribute Details No. of Pages 400 Forecast Period 2025-2034 Estimated Market Value (USD) in 2025 $1.34 Billion Forecasted Market Value (USD) by 2034 $2.07 Billion Compound Annual Growth Rate 4.4% Regions Covered Global Key Topics Covered1 Preface1.1 Objectives of the Study1.2 Key Assumptions1.3 Report Coverage - Key Segmentation and Scope1.4 Research Methodology2 Executive Summary3 Zollinger Ellison Syndrome Market Overview - 8 Major Markets3.1 Zollinger Ellison Syndrome Market Historical Value (2018-2024)3.2 Zollinger Ellison Syndrome Market Forecast Value (2025-2034)4 Vendor Positioning Analysis4.1 Key Vendors4.2 Prospective Leaders4.3 Niche Leaders4.4 Disruptors5 Zollinger Ellison Syndrome Overview5.1 Guidelines and Stages5.2 Pathophysiology5.3 Screening and Diagnosis5.4 Treatment Pathway6 Patient Profile6.1 Patient Profile Overview6.2 Patient Psychology and Emotional Impact Factors6.3 Risk Assessment and Treatment Success Rate7 Zollinger Ellison Syndrome Market - Epidemiology Scenario and Forecast - 8 Major Markets7.1 8MM Epidemiology Scenario Overview (2018-2034)7.2 Prevalence, by Country7.3 Diagnosed Cases, by Country7.4 Treatment Seeking Rate, by Country8 Zollinger Ellison Syndrome Market Landscape - 8 Major Markets8.1 Zollinger Ellison Syndrome Market: Developers Landscape8.1.1 Analysis by Year of Establishment8.1.2 Analysis by Company Size8.1.3 Analysis by Region8.2 Zollinger Ellison Syndrome Market: Product Landscape8.2.1 Analysis by Treatment Type9 Zollinger Ellison Syndrome Market Challenges and Unmet Needs9.1 Treatment Pathway Challenges9.2 Compliance and Drop-Out Analysis9.3 Awareness and Prevention Gaps10 Cost of Treatment11 Zollinger Ellison Syndrome Market Dynamics11.1 Market Drivers and Constraints11.2 SWOT Analysis11.2.1 Strengths11.2.2 Weaknesses11.2.3 Opportunities11.2.4 Threats11.3 PESTEL Analysis11.3.1 Political11.3.2 Economic11.3.3 Social11.3.4 Technological11.3.5 Legal11.3.6 Environment11.4 Porter's Five Forces Model11.4.1 Bargaining Power of Suppliers11.4.2 Bargaining Power of Buyers11.4.3 Threat of New Entrants11.4.4 Threat of Substitutes11.4.5 Degree of Rivalry11.5 Key Demand Indicators11.6 Key Price Indicators11.7 Industry Events, Initiatives, and Trends11.8 Value Chain Analysis12 Zollinger Ellison Syndrome Market Segmentation (218-2034) - 8 Major Markets12.1 Zollinger Ellison Syndrome Market (2018-2034) by Treatment12.2 Zollinger Ellison Syndrome Market (2018-2034) by Distribution Channel12.3 Zollinger Ellison Syndrome Market (2018-2034) by End User12.4 Zollinger Ellison Syndrome Market (2018-2034) by Region 13 United States Zollinger Ellison Syndrome Market (218-2034) 14 United Kingdom Zollinger Ellison Syndrome Market (218-2034) 15 Germany Zollinger Ellison Syndrome Market (218-2034) 16 France Zollinger Ellison Syndrome Market (218-2034) 17 Italy Zollinger Ellison Syndrome Market (218-2034) 18 Spain Zollinger Ellison Syndrome Market (218-2034) 19 Japan Zollinger Ellison Syndrome Market (218-2034) 20 India Zollinger Ellison Syndrome Market (218-2034) 21 Regulatory Framework21.1 Regulatory Overview21.2 US FDA21.3 EU EMA21.4 Japan PMDA21.5 India CDSCO21.6 Others 22 Patent Analysis22.1 Analysis by Type of Patent22.2 Analysis by Publication Year22.3 Analysis by Issuing Authority22.4 Analysis by Patent Age22.5 Analysis by CPC Analysis22.6 Analysis by Patent Valuation 23 Clinical Trials Analysis23.1 Analysis by Trial Registration Year23.2 Analysis by Trial Status23.3 Analysis by Trial Phase23.4 Analysis by Therapeutic Area23.5 Analysis by Geography 24 Grants Analysis24.1 Analysis by Year24.2 Analysis by Amount Awarded24.3 Analysis by Issuing Authority24.4 Analysis by Grant Application24.5 Analysis by Funding Institute24.6 Analysis by NIH Departments24.7 Analysis by Recipient Organization 25 Funding and Investment Analysis25.1 Analysis by Funding Instances25.2 Analysis by Drug Class of Funding25.3 Analysis by Funding Amount25.4 Analysis by Leading Players25.5 Analysis by Leading Investors25.6 Analysis by Geography 26 Strategic Initiatives26.1 Analysis by Partnership Instances26.2 Analysis by Drug Class of Partnership26.3 Analysis by Leading Players26.4 Analysis by Geography 27 Supplier Landscape27.1 Market Share Analysis, By Region (Top 5 Companies)27.2 Novartis AG27.3 GSK PLC27.4 Bayer AG27.5 Pfizer Inc.27.6 Bristol Myers Squibb Company27.7 Mylan N.V.27.8 Teva Pharmaceutical Industries Ltd.27.9 Johnson & Johnson Services, Inc.27.10 Lupin Limited27.11 Alembic Pharmaceuticals Limited27.12 Baxter International Inc. 28 Zollinger Ellison Syndrome Market - Distribution Model (Additional Insight)28.1 Overview28.2 Potential Distributors28.3 Key Parameters for Distribution Partner Assessment29 Key Opinion Leaders (KOL) Insights (Additional Insight)30 Payment Methods (Additional Insight)30.1 Government Funded30.2 Private Insurance30.3 Out-of-PocketFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Zollinger Ellison Syndrome Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
20 hours ago
- Business
- Globe and Mail
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
Tempus AI TEM, a Chicago-based company focused on precision medicine, is building network effects via its three interconnected product lines. In the first quarter of 2025, revenues in its Data and Services segment increased 43.2% year over year to $61.9 million, driven by a 58% growth in Insights, the company's data licensing business. Gross profit outpaced revenue growth, up 65.2% with only a modest 3% increase in the cost of revenues. The business has scaled significantly, securing deals with companies like Novartis, Merck EMD, Takeda and United Therapeutics over the past year. Against that backdrop, Tempus' ability to sustain such strong growth rates in Data and Services is particularly impressive. Most of these contracts span multiple years, with total remaining contract value reflecting data and services yet to be delivered. Several recent developments are setting the stage for the momentum to continue. A major highlight is Tempus AI's $200 million data and modeling license agreement with AstraZeneca AZN and Pathos to build the world's largest foundation model, bringing AZN's total remaining contract value to over $1 billion as of April 30. AZN and Pathos are also covering a large portion of the compute costs to train the model. Notably, the agreement's non-exclusive nature allows Tempus to license data and build models with others in the future. The company also expanded its collaboration with Illumina, which will use its multimodal data platform to accelerate clinical benefits of molecular profiling across all major diseases. In May, Tempus inked a large data agreement with Boehringer Ingelheim focused on biomarker development and novel discovery efforts, building on their past collaboration. Further, the company's new oncology-focused platform, Loop, is already in use by a large pharmaceutical company to prioritize drug targets in patient subpopulations with severe unmet needs. TEM's Key Competitors in Data and Services ICON ICLR, an Ireland-based contract research organization, experienced a significant increase in overall biotech opportunities and a modest uptick in project win rates in the first quarter of 2025. However, it was ultimately offset by an increased number of customer-cancelled request for proposal (RFP) opportunities. In large pharma, RFP opportunities were softer in the quarter; still, ICLR's high success rate underscored its strong positioning as a strategic partner. IQVIA 's IQV Technology & Analytics Solutions business continued the strong recovery trend in the first quarter of 2025, with clients launching new drugs and executing their commercial roadmaps. However, IQV faced slower decision-making from clinical customers on new programs, reflecting broader macroeconomic pressure and industry caution. IQVIA reported a 10% increase in average time from RFP issuance to award in the quarter, both year over year and sequentially. TEM Outperforms Peers, Industry, But Valuation Stretched Year to date, Tempus AI shares have surged 102.5%, outperforming the industry's 18% growth and also delivering stronger returns than IQV and ICLR. Image Source: Zacks Investment Research TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 8.47X compared to the industry average of 5.83X. Image Source: Zacks Investment Research TEM Stock Estimate Trend As you can see, earnings estimates for Tempus AI in 2025 and 2026 are showing a mixed picture. TEM stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report ICON PLC (ICLR): Free Stock Analysis Report IQVIA Holdings Inc. (IQV): Free Stock Analysis Report Tempus AI, Inc. (TEM): Free Stock Analysis Report This article originally published on Zacks Investment Research (
Yahoo
2 days ago
- Business
- Yahoo
BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Relay Therapeutics, Inc. (NASDAQ:RLAY) on June 3 and set a price target of $17.00. The rating update came after the company announced updated interim clinical data for RLY-2608 on June 2. A chemist arranging containers of compounds, ready for the commercialization process. RLY-2608 is the first known investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα. The updated interim data remained consistent with the data previously shared in December 2024, showing a '10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer.' The data continues to support the planned pivotal study initiation in mid-2025. Relay Therapeutics, Inc. (NASDAQ:RLAY) is a clinical-stage precision medicine company that uses advanced computational and experimental technologies to innovate drug discovery. Its primary focus is on genetic disease indications and targeted oncology. The company's Dynamo platform integrates a range of cutting-edge experimental and computational approaches to understand protein structure and motion in drug discovery. While we acknowledge the potential of RLAY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
4 days ago
- Business
- Yahoo
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
FORT MYERS, Fla., June 24, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue and pipeline investment. "We are thrilled to welcome Marjorie to the NeoGenomics Board," said Lynn Tetrault, Chair of the Board of NeoGenomics. "Dr. Green's deep expertise in clinical oncology and pipeline development, combined with her experience in business development, will be invaluable as we continue to accelerate innovation into the precision oncology market." Prior to joining Merck, Dr. Green served as Senior Vice President and Head of Late-Stage Development at Seagen. Prior to that, Dr. Green was Vice President of Product Development and Global Head of the Breast and Gynecologic Cancer Franchise at Genentech. She began her career as a Medical Oncologist and Associate Professor at MD Anderson Cancer Center where she later became the Medical Director of the Nellie B. Connally Breast Center. Dr. Green earned her BA in History from the University of Notre Dame and her MD from the University of Texas Medical Branch. She completed her residency in internal medicine at the University of Virginia School of Medicine and her medical oncology fellowship at the University of Texas MD Anderson Cancer Center. "I am honored to join NeoGenomics' Board at such an exciting time in the company's journey," said Dr. Marjorie Green. "Neo's unique oncology diagnostics offerings are well positioned for growth, and I look forward to contributing to the company's mission of improving patient care." About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "guidance," "plan," "potential" and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on Contacts Investor Contact Kendra Sweeneyir@ Media Contact Andrea Sampsonasampson@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
